Standard Biotools Inc (LAB) Stock Price, Quote & News

Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 266 6000

Fax: 650 871 7152

Website: www.standardbio.com

Address:

2 Tower Place, Suite 2000, South San Francisco, United States

DonWestTrading Jan. 13 at 4:29 PM

$LAB standard TOOLS is right. I would not use in my lab.

1 · Reply

WHO905 Jan. 13 at 4:25 PM

$LAB $PACB Really tired of watching the algorithms control the pricing on these stocks. It will be really nice to each trade on its own merit with true institutional interest. Market Cap on LAB would be at least $1.5B!

2 · Reply

Jdfulgham1990 Jan. 13 at 3:44 PM

$LAB volume starting to increase up 5% today and up almost 25% since last week. Low float with heavy support level around $1.50 and short interest currently around 5%. Could move up quickly once volume starts increasing 💪 Also watching $BYND and $PLUG

0 · Reply

Jdfulgham1990 Jan. 13 at 2:36 PM

Watching both $LAB and $BYND for the next leg up🧨🚀 both have been consolidating nicely building support!!

0 · Reply

Xanderzzzzzzz Jan. 8 at 2:04 PM

$LAB

0 · Reply

beckphan08 Jan. 8 at 1:32 PM

$LAB 2026 is going to be the year!

0 · Reply

goofyfoot Jan. 7 at 11:09 PM

$LAB Yep!

0 · Reply

Zachary192 Jan. 3 at 8:10 PM

$LAB

0 · Reply

Wisenheimer Dec. 29 at 4:46 PM

$LAB hit the metrics for high risk of reverse stock split

0 · Reply

Xanderzzzzzzz Dec. 29 at 2:17 PM

$LAB Standard BioTools is trading near cash value post-SomaScan sale, with Casdin Capital raising its stake to 25%. LAB will receive $350M upfront and up to $75M in earnouts from Illumina for SomaScan, leaving $550M in cash post-transaction. Management projects Adj. EBITDA breakeven in 2026 after divestiture and a 20% workforce reduction

0 · Reply

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

Nov 19, 2025, 11:30 AM EST - 2 months ago

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Nov 10, 2025, 12:15 PM EST - 2 months ago

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

ILMN

Nov 4, 2025, 4:05 PM EST - 2 months ago

Standard BioTools Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 7:00 AM EDT - 3 months ago

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Sep 3, 2025, 9:15 AM EDT - 4 months ago

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

ILMN

Aug 11, 2025, 4:01 PM EDT - 5 months ago

Standard BioTools Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 5 months ago

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

Jul 21, 2025, 7:00 AM EDT - 6 months ago

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

Jun 23, 2025, 7:13 AM EDT - 7 months ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

ILMN

Jun 23, 2025, 7:05 AM EDT - 7 months ago

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

May 30, 2025, 7:00 AM EDT - 8 months ago

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series

May 6, 2025, 8:08 PM EDT - 9 months ago

Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript

May 6, 2025, 4:01 PM EDT - 9 months ago

Standard BioTools Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:00 AM EDT - 9 months ago

Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025

Apr 22, 2025, 7:00 AM EDT - 9 months ago

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Feb 27, 2025, 4:01 PM EST - 11 months ago

Standard BioTools to Participate in Upcoming Investor Conferences

Feb 26, 2025, 9:44 PM EST - 11 months ago

Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:01 PM EST - 11 months ago

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 1 year ago

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 8:00 AM EST - 1 year ago

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 7, 2024, 8:00 AM EST - 1 year ago

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Oct 30, 2024, 7:10 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports Third Quarter 2024 Financial Results

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024

Aug 28, 2024, 8:58 AM EDT - 1 year ago

Standard BioTools And 2 Other Penny Stocks Executives Are Buying

Aug 27, 2024, 9:15 AM EDT - 1 year ago

Standard BioTools And 3 Other Stocks Under $3 Executives Are Buying

Jul 31, 2024, 8:34 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:02 PM EDT - 1 year ago

Standard BioTools Announces Senior Leadership Changes

Jul 31, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 8:01 AM EDT - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024

May 28, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers

May 23, 2024, 9:17 AM EDT - 1 year ago

Lab Instrument Industry Update - New Commercial Entrants

AKYA BNGO CTKB DHR MASS OMIC QGEN

May 20, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 11, 2024, 12:45 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:01 AM EDT - 1 year ago

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

Apr 3, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

Mar 18, 2024, 8:12 AM EDT - 1 year ago

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

Feb 28, 2024, 8:44 PM EST - 2 years ago

Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:01 PM EST - 2 years ago

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Feb 7, 2024, 8:30 AM EST - 2 years ago

Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Jan 8, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Jan 5, 2024, 8:46 AM EST - 2 years ago

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

Jan 4, 2024, 10:23 PM EST - 2 years ago

Standard BioTools Stockholders Approve Merger with SomaLogic

Jan 4, 2024, 9:44 PM EST - 2 years ago

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

Dec 31, 2023, 2:10 PM EST - 2 years ago

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

DonWestTrading Jan. 13 at 4:29 PM

$LAB standard TOOLS is right. I would not use in my lab.

1 · Reply

WHO905 Jan. 13 at 4:25 PM

2 · Reply

Jdfulgham1990 Jan. 13 at 3:44 PM

0 · Reply

Jdfulgham1990 Jan. 13 at 2:36 PM

Watching both $LAB and $BYND for the next leg up🧨🚀 both have been consolidating nicely building support!!

0 · Reply

Xanderzzzzzzz Jan. 8 at 2:04 PM

$LAB

0 · Reply

beckphan08 Jan. 8 at 1:32 PM

$LAB 2026 is going to be the year!

0 · Reply

goofyfoot Jan. 7 at 11:09 PM

$LAB Yep!

0 · Reply

Zachary192 Jan. 3 at 8:10 PM

$LAB

0 · Reply

Wisenheimer Dec. 29 at 4:46 PM

$LAB hit the metrics for high risk of reverse stock split

0 · Reply

Xanderzzzzzzz Dec. 29 at 2:17 PM

0 · Reply

Sunugal780 Dec. 29 at 1:41 AM

$LAB Something is brewing: a volume of 1.07M @$1.50 half hour ago.

1 · Reply

MindfulMyth Dec. 27 at 3:28 PM

$LAB Market participants want evidence that strategy converts to numbers; organic growth must prove sustainable without incentives — stable fundamentals would matter more than macro swings. Only demonstrated reliability will sustain upside potential.

0 · Reply

ExoticPairE Dec. 25 at 1:14 PM

$LAB The strategic path forward will be judged on practical milestones, not narrative strength. Execution reliability across quarters will determine whether confidence can compound. If milestones arrive on time, perception can shift faster than fundamentals. Catalysts help, but operating proof ultimately carries the most weight.

0 · Reply

Stanleydavidson Dec. 24 at 4:56 PM

$LAB imagine the price when they finalise deal early 2026 with $ILMN Of 425 millllion $

0 · Reply

Jkpga Dec. 24 at 3:16 PM

$LAB that was a false run

0 · Reply

Stanleydavidson Dec. 24 at 1:03 PM

$LAB $ILMN the deal will close early 2026 !!! Lab will receive almost 1/2 billion for sale of is somalogic departement and concentrate on biotools after $$$

0 · Reply

Stanleydavidson Dec. 24 at 12:45 AM

$LAB if the boss bought fir 10 million 2026 gone a be great 4-5$ on the way

0 · Reply

Xanderzzzzzzz Dec. 23 at 6:50 PM

$LAB

0 · Reply

IamAnderson Dec. 23 at 4:31 PM

$LAB why is everybody so quiet today

1 · Reply

beckphan08 Dec. 22 at 3:34 PM

$LAB $10 (Trying to manifest this lol)

0 · Reply

Jkpga Dec. 22 at 3:31 PM

$LAB she’s hot!

1 · Reply

Xanderzzzzzzz Dec. 20 at 4:40 PM

$LAB

0 · Reply

Market Cap	580.69M
Revenue (ttm)	174.43M
Net Income (ttm)	-138.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-79.63%
Debt to Equity Ratio	0.00

Volume	2,234,000
Avg Vol	1,865,050
Day's Range	N/A - N/A
Shares Out	384.57M
Stochastic %K	93%
Beta	1.26
Analysts	Sell
Price Target	$1.55